Lenvatinib is an oral multi-target tyrosine kinase inhibitor that can inhibit VEGFR and FGFR through multiple pathways, thereby suppressing tumor angiogenesis, metastasis, and progression (11). This evidence concerns the gene KDR and neoplasm.